Oncology News | pharmaphorum

News

Setback for J&J's TAR-200 bladder cancer programme

A phase 3 trial of Johnson & Johnson's TAR-200 therapy in bladder cancer has failed to show efficacy, although the company is still confident in the potential of the programme.

News

digital pathology slide from breast cancer screening

AZ and Owkin partner on AI to speed up BRCA testing

Testing for BRCA mutations linked to breast and ovarian cancers could become easier and more accessible with the help of artificial intelligence, potentially allowing earlier treatment.

News

AZ gets sought-after lung cancer approval for Tagrisso

AstraZeneca's EGFR inhibitor Tagrisso has been approved by the FDA for a new lung cancer indication that could make it a go-to therapy for a patient population that until now had no targete

News

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

News

Astellas claims EU okay for first claudin 18.2 cancer drug

The EU has followed Japan and GB in approving Astellas' first-to-market claudin 18.2-targeted therapy Vyloy, clearing it for gastric and gastroesophageal junction (GEJ) cancer.

News

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Sanofi's Sarclisa has been an also-ran in the anti-CD38 antibody class behind Johnson & Johnson and Genmab's blockbuster Darzalex, but now has a chance to steal some of the spotlight.

Setback for J&J's TAR-200 bladder cancer programme

AZ and Owkin partner on AI to speed up BRCA testing

AZ gets sought-after lung cancer approval for Tagrisso

MSD hits a hurdle with its LAG-3 programme

Astellas claims EU okay for first claudin 18.2 cancer drug

Sanofi's Sarclisa gets one up on rival Darzalex in myeloma

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

News

Editor's Picks